ストックスクリーナーアプリを入手
2.05
7.66%
-0.17
プレマーケット:
2.05
前日終値:
$2.22
開ける：
$2.22
24時間の取引高:
7.80M
Relative Volume:
1.46
時価総額：
$526.46M
収益：
$403.14M
当期純損益:
$-22.68M
株価収益率:
-9.7852
EPS:
-0.2095
ネットキャッシュフロー:
$-13.09M
1週間 パフォーマンス:
-11.26%
1か月 パフォーマンス:
-15.98%
6か月 パフォーマンス:
-24.07%
1年 パフォーマンス:
+105.18%
1日の値動き範囲:
$2.03
$2.27
1週間の範囲:
$2.03
$2.46
52週間の値動き範囲:
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
名前
Esperion Therapeutics Inc
セクター
電話
734-887-3903
住所
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.05 | 557.28M | 403.14M | -22.68M | -13.09M | -0.2095 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-25 | 開始されました | Piper Sandler | Overweight |
| 2024-12-18 | 開始されました | Goldman | Neutral |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-01 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | アップグレード | BofA Securities | Underperform → Buy |
| 2023-03-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-03-16 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 再開されました | BofA Securities | Neutral |
| 2023-02-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-19 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-12 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-09 | ダウングレード | Goldman | Neutral → Sell |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-10 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Underweight |
| 2020-08-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 再開されました | BofA/Merrill | Buy |
| 2020-03-17 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-24 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-16 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-29 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | アップグレード | Goldman | Sell → Neutral |
| 2019-03-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 繰り返されました | Needham | Strong Buy |
| 2018-12-13 | 開始されました | Goldman | Sell |
| 2018-10-29 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2018-07-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-05-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
すべてを表示
Esperion Therapeutics Inc (ESPR) 最新ニュース
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Esperion Therapeutics, Inc. (ESPR) Latest Stock News & Headlines - Yahoo Finance
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference - Yahoo Finance
Personalized treatments advance as Esperion Therapeutics urges broader use of hsCRP in heart care - Traders Union
Esperion Therapeutics, Inc. (ESPR) latest stock news and headlines - Yahoo Finance Singapore
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Esperion (ESPR) highlights inclusion of bempedoic acid in 2026 ACC/AHA dyslipidemia guidelines - MSN
Guidance Update: What is the next catalyst for Esperion Therapeutics Inc2026 Drop Watch & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Movement Recap: What are Esperion Therapeutics Incs technical support levels2026 Price Targets & Weekly Return Optimization Alerts - baoquankhu1.vn
ESPR Forecast, Price Target & Analyst Ratings | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics Stock Dips After Q4 Earnings Miss Expectations - StocksToTrade
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ann Arbor pharmaceutical company acquires nasal spray treatment manufacturer - MLive.com
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co. - MarketBeat
This Cheap $2.60's Stock Is A Great Investment With Huge Guideline News. Top 3 Analysts Say Strong Buy $9 to $16 - Moomoo
ESPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Esperion Therapeutics, Inc. (ESPR) stock price, news, quote and history - Yahoo Finance UK
Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio - The Globe and Mail
Esperion sells Japan royalty rights for $50 million to Athyrium By Investing.com - Investing.com Canada
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - Sahm
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics - The Manila Times
Athyrium Capital Management and Esperion Therapeutics Inc. (NASDAQ: ESPR) have signed a Japanese royalty financing agreement worth $50 million - Bitget
Esperion Therapeutics Enters First Amendment To Credit Agreement On April 2, 2026SEC Filing - TradingView — Track All Markets
Esperion Therapeutics, Athyrium Capital Management Sign $50 Million Japan Royalty Financing - marketscreener.com
Esperion Therapeutics Inc. has successfully secured financing, which will be specifically used to support its acquisition of Corstasis Therapeutics. - Bitget
Esperion Therapeutics Inc. (ESPR) has entered into a new financial arrangement with the Athyrium Fund. - Bitget
Esperion Adds $25 Million Term Loans, Sells $50 Million Otsuka Royalties to Fund Corstasis Buy - TradingView — Track All Markets
Esperion (ESPR) acquires Corstasis, adds $25M term loan and $50M royalty sale - Stock Titan
Esperion sells Japan royalty rights for $50 million to Athyrium - Investing.com
Esperion completes acquisition of Corstasis Therapeutics - Investing.com
Athyrium Capital Management and Esperion Enter Into $50 - GlobeNewswire
Esperion Therapeutics ranks 88 among 300 on Americas Fastest Growing Companies list - Traders Union
Zacks Research Has Negative Forecast for ESPR Q2 Earnings - MarketBeat
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) - Bitget
Esperion Presents New Data from CLEAR Outcomes Highlighting Value of Bempedoic Acid at ACC.26 - dicardiology.com
Esperion Therapeutics, Inc. completed the acquisition of Corstasis Therapeutics Inc. - marketscreener.com
New Analyst Updates: $9 and $16 Price Targets on Esperion Therapeutics Signal Major Upside From $2.63 - Moomoo
Q4 EPS Estimate for Esperion Therapeutics Raised by Analyst - MarketBeat
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing - citybiz
Esperion Therapeutics Inc (ESPR) strengthens business outlook amid strategic agreements - MSN
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference - Bitget
Esperion to acquire Corstasis for $75M upfront payment - MSN
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.7%Here's What Happened - MarketBeat
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Investors can watch Esperion at Needham's virtual healthcare event - Stock Titan
US Market Wrap: Can Esperion Therapeutics Inc outperform under higher oil prices2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Needham Virtual Healthcare Conference features Esperion Therapeutics at 25th anniversary session - Traders Union
Esperion reports bempedoic acid cut ischemic stroke risk by 22% - Investing.com Canada
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 - Bitget
Esperion Therapeutics unveils new CLEAR Outcomes data on NEXLETOL at ACC Annual Scientific Session - Traders Union
Esperion Showcases New Data from CLEAR Outcomes - GlobeNewswire
Esperion Therapeutics Inc (ESPR) 財務データ
収益
当期純利益
現金流量
EPS
1.06%
1.05%
大文字化:
|
ボリューム (24 時間):